Schreckenberg, R.; Wolf, A.; Szabados, T.; Gömöri, K.; Szabó, I.A.; Ágoston, G.; Brenner, G.; Bencsik, P.; Ferdinandy, P.; Schulz, R.;
et al. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. Int. J. Mol. Sci. 2022, 23, 6512.
https://doi.org/10.3390/ijms23126512
AMA Style
Schreckenberg R, Wolf A, Szabados T, Gömöri K, Szabó IA, Ágoston G, Brenner G, Bencsik P, Ferdinandy P, Schulz R,
et al. Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. International Journal of Molecular Sciences. 2022; 23(12):6512.
https://doi.org/10.3390/ijms23126512
Chicago/Turabian Style
Schreckenberg, Rolf, Annemarie Wolf, Tamara Szabados, Kamilla Gömöri, István Adorján Szabó, Gergely Ágoston, Gábor Brenner, Péter Bencsik, Péter Ferdinandy, Rainer Schulz,
and et al. 2022. "Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo" International Journal of Molecular Sciences 23, no. 12: 6512.
https://doi.org/10.3390/ijms23126512
APA Style
Schreckenberg, R., Wolf, A., Szabados, T., Gömöri, K., Szabó, I. A., Ágoston, G., Brenner, G., Bencsik, P., Ferdinandy, P., Schulz, R., & Schlüter, K.-D.
(2022). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo. International Journal of Molecular Sciences, 23(12), 6512.
https://doi.org/10.3390/ijms23126512
